AR018622A1 - COMPOUNDS (S) - (-) - 1- [1- (4-SUBSTITUTED OR NOT REPLACED, 2-METOXIFENIL) PIPERID-4-IL] -N- (7-TRIFLUOROMETIL-2,3-DIHIDRO-1,4- BENZODIOXIN-2-IL METIL) METHYLAMINE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, ITS USE TO PREPARE A MEDICINAL PRODUCT AND PROCEDURE TO PREPARE THEM - Google Patents
COMPOUNDS (S) - (-) - 1- [1- (4-SUBSTITUTED OR NOT REPLACED, 2-METOXIFENIL) PIPERID-4-IL] -N- (7-TRIFLUOROMETIL-2,3-DIHIDRO-1,4- BENZODIOXIN-2-IL METIL) METHYLAMINE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, ITS USE TO PREPARE A MEDICINAL PRODUCT AND PROCEDURE TO PREPARE THEMInfo
- Publication number
- AR018622A1 AR018622A1 ARP990102619A ARP990102619A AR018622A1 AR 018622 A1 AR018622 A1 AR 018622A1 AR P990102619 A ARP990102619 A AR P990102619A AR P990102619 A ARP990102619 A AR P990102619A AR 018622 A1 AR018622 A1 AR 018622A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- prepare
- formula
- compounds
- piperid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 title 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000027776 Extrapyramidal disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000607 neurosecretory system Anatomy 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
Compuestos (S)-(-)-1-[1-(4-sustituido o no sustituido, 2-metoxifenil)piperid-4-il]-N-(7-trifluorometil-2,3-dihidro-1,4-benzodioxin-2-ilmetil)metilamina deformula (I) incluyendo a sales farmacéuticamente aceptables de los mismos, en los cuales R representa a H o F que presentan actividad y selectividad aumentadasfrente a lo conocido y son de utilidad como agentes terapéuticos que tienen receptores de S-HT1A y/o alfa1 y/o D2. Composiciones farmacéuticas que comprendenuna cantidad terapéuticamenteefectiva de dicho compuesto junto con un diluyente o vehículo farmacéuticamente aceptable. Uso de un compuesto de formula (I)segun lo descripto para la elaboracion de un medicamento para el tratamiento de la depresion, ansiedad, psicosis, disquinesiatardía, mal de Parkinson,obesidad, hipertension, síndrome de Tourette, disfuncion sexual, adiccion a las drogas, abuso de drogas, desordenes cognoscitivos, enfermedad de Alzheimer,demencia senil, conducta obsesiva-compulsiva, ataques de pánico, desordenes de la alimentacion, anorexia, desordenes cardiovasculares y cerebrovasculares,migrana, diabetes mellitus no insulino-dependiente, hiperglucemia, constipacion, arritmia, desordenes del sistema neuroendocrino, estrés, hipertrofiaprostática, síntomas extrapiramidales drogo-inducidos o espasticidad, en donde dicho tratamiento comprende la administracion de una cantidad terapéuticamenteefectiva del compuesto a un paciente necesitado de la misma. Un procedimiento para preparar dichos compuestosde formula (I) que comprende hacer reaccionar uncompuesto de formula (II) en el cual Z es un grupo saliente, con un compuesto de formula (III) en el cual R tiene la misma definicion dada anteriormente,opcionalmente en presencia de un solvente o mezcla de solventes adecuados, opcionalmente en presencia de una base, a una temperatura en el rango de 0-250*C.Compounds (S) - (-) - 1- [1- (4-substituted or unsubstituted, 2-methoxyphenyl) piperid-4-yl] -N- (7-trifluoromethyl-2,3-dihydro-1,4- benzodioxin-2-ylmethyl) methylamine deformula (I) including pharmaceutically acceptable salts thereof, in which R represents H or F that have increased activity and selectivity in front of the known and are useful as therapeutic agents that have S receptors -HT1A and / or alpha1 and / or D2. Pharmaceutical compositions comprising a therapeutically effective amount of said compound together with a pharmaceutically acceptable diluent or carrier. Use of a compound of formula (I) as described for the preparation of a medicament for the treatment of depression, anxiety, psychosis, dyskinesiatariad, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction , drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behavior, panic attacks, eating disorders, anorexia, cardiovascular and cerebrovascular disorders, migraine, non-insulin-dependent diabetes mellitus, hyperglycemia, constipation, arrhythmia , neuroendocrine system disorders, stress, hypertrophyprostatic, drug-induced extrapyramidal symptoms or spasticity, wherein said treatment comprises the administration of a therapeutically effective amount of the compound to a patient in need thereof. A process for preparing said compounds of formula (I) comprising reacting an compound of formula (II) in which Z is a leaving group, with a compound of formula (III) in which R has the same definition given above, optionally in presence of a suitable solvent or mixture of solvents, optionally in the presence of a base, at a temperature in the range of 0-250 * C.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9811879.7A GB9811879D0 (en) | 1998-06-03 | 1998-06-03 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018622A1 true AR018622A1 (en) | 2001-11-28 |
Family
ID=10833098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102619A AR018622A1 (en) | 1998-06-03 | 1999-06-03 | COMPOUNDS (S) - (-) - 1- [1- (4-SUBSTITUTED OR NOT REPLACED, 2-METOXIFENIL) PIPERID-4-IL] -N- (7-TRIFLUOROMETIL-2,3-DIHIDRO-1,4- BENZODIOXIN-2-IL METIL) METHYLAMINE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, ITS USE TO PREPARE A MEDICINAL PRODUCT AND PROCEDURE TO PREPARE THEM |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1087964A1 (en) |
| JP (1) | JP2002517392A (en) |
| KR (1) | KR20010052526A (en) |
| CN (1) | CN1304408A (en) |
| AR (1) | AR018622A1 (en) |
| AU (1) | AU4369599A (en) |
| BG (1) | BG104988A (en) |
| BR (1) | BR9910927A (en) |
| CA (1) | CA2333756A1 (en) |
| CO (1) | CO5021190A1 (en) |
| GB (1) | GB9811879D0 (en) |
| HR (1) | HRP20010005A2 (en) |
| HU (1) | HUP0102233A2 (en) |
| ID (1) | ID27067A (en) |
| IL (1) | IL139552A0 (en) |
| NO (1) | NO20006041D0 (en) |
| PL (1) | PL344594A1 (en) |
| SK (1) | SK17602000A3 (en) |
| TR (1) | TR200003569T2 (en) |
| WO (1) | WO1999062902A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9915616D0 (en) * | 1999-07-05 | 1999-09-01 | Knoll Ag | Therapeutic agents |
| GB0007376D0 (en) * | 2000-03-28 | 2000-05-17 | Knoll Ag | Therapeutic agents |
| CA2405758A1 (en) * | 2000-05-12 | 2001-11-15 | Solvay Pharmaceuticals B.V. | Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders |
| CA2405971C (en) * | 2000-05-12 | 2010-03-30 | Solvay Pharmaceuticals B.V. | New piperazine and piperidine compounds |
| BRPI0510642A (en) * | 2004-05-05 | 2007-11-20 | Hoffmann La Roche | arylsulfonyl benzodioxanes useful for modulating 5-ht6 receptor, 5ht2a receptor or both |
| PA8663501A1 (en) | 2005-02-17 | 2006-11-09 | Wyeth Wyeth | DERIVATIVES OF INDOL, BENZOTIOFEN, BENZOFURAN AND INDENO CICLOALQUILCONDENSADOS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2681325B1 (en) * | 1991-09-16 | 1993-12-17 | Fabre Medicament Pierre | DERIVATIVES OF AMINOMETHYL-4 PIPERIDINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. |
| FR2701479B1 (en) * | 1993-02-11 | 1995-05-12 | Pf Medicament | New heterocyclic derivatives of 4-aminomethyl piperidine, their preparation and their therapeutic use. |
| GB9318431D0 (en) * | 1993-09-06 | 1993-10-20 | Boots Co Plc | Therapeutic agents |
| GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
-
1998
- 1998-06-03 GB GBGB9811879.7A patent/GB9811879D0/en not_active Ceased
-
1999
- 1999-05-26 KR KR1020007013670A patent/KR20010052526A/en not_active Withdrawn
- 1999-05-26 HR HR20010005A patent/HRP20010005A2/en not_active Application Discontinuation
- 1999-05-26 EP EP99926434A patent/EP1087964A1/en not_active Ceased
- 1999-05-26 WO PCT/EP1999/003648 patent/WO1999062902A1/en not_active Ceased
- 1999-05-26 JP JP2000552113A patent/JP2002517392A/en active Pending
- 1999-05-26 CN CN99806908A patent/CN1304408A/en active Pending
- 1999-05-26 SK SK1760-2000A patent/SK17602000A3/en unknown
- 1999-05-26 PL PL99344594A patent/PL344594A1/en not_active Application Discontinuation
- 1999-05-26 IL IL13955299A patent/IL139552A0/en unknown
- 1999-05-26 TR TR2000/03569T patent/TR200003569T2/en unknown
- 1999-05-26 AU AU43695/99A patent/AU4369599A/en not_active Abandoned
- 1999-05-26 HU HU0102233A patent/HUP0102233A2/en unknown
- 1999-05-26 BR BR9910927-1A patent/BR9910927A/en not_active IP Right Cessation
- 1999-05-26 CA CA002333756A patent/CA2333756A1/en not_active Abandoned
- 1999-05-26 ID IDW20002519A patent/ID27067A/en unknown
- 1999-06-03 CO CO99035020A patent/CO5021190A1/en unknown
- 1999-06-03 AR ARP990102619A patent/AR018622A1/en not_active Application Discontinuation
-
2000
- 2000-11-27 BG BG104988A patent/BG104988A/en unknown
- 2000-11-29 NO NO20006041A patent/NO20006041D0/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1304408A (en) | 2001-07-18 |
| ID27067A (en) | 2001-02-22 |
| PL344594A1 (en) | 2001-11-05 |
| AU4369599A (en) | 1999-12-20 |
| EP1087964A1 (en) | 2001-04-04 |
| NO20006041L (en) | 2000-11-29 |
| BG104988A (en) | 2001-11-30 |
| TR200003569T2 (en) | 2001-04-20 |
| IL139552A0 (en) | 2002-02-10 |
| CO5021190A1 (en) | 2001-03-27 |
| KR20010052526A (en) | 2001-06-25 |
| SK17602000A3 (en) | 2001-08-06 |
| GB9811879D0 (en) | 1998-07-29 |
| HRP20010005A2 (en) | 2001-12-31 |
| CA2333756A1 (en) | 1999-12-09 |
| BR9910927A (en) | 2001-02-20 |
| WO1999062902A1 (en) | 1999-12-09 |
| NO20006041D0 (en) | 2000-11-29 |
| HUP0102233A2 (en) | 2002-05-29 |
| JP2002517392A (en) | 2002-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2435432B3 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| DE60126344T2 (en) | ISOINDOLIMIDE COMPOUNDS, COMPOSITIONS AND USES | |
| JPH09502431A (en) | Bicyclic aromatic compounds as therapeutic agents | |
| EP2308562B1 (en) | Azetidine ring compounds and drugs comprising the same | |
| JPS5995269A (en) | Antiepileptic | |
| Varró et al. | The First Enantioselective Total Synthesis of (−)-trans-Dihydronarciclasine | |
| CN1179422A (en) | New flavone compounds, process for preparing them and pharmaceutical compositions containing them | |
| CA2596355A1 (en) | Tumor necrosis factor inhibitors | |
| JPH04500362A (en) | Novel 8-substituted-2-aminotetralins | |
| CN102134245A (en) | Tetralin isoquinoline compounds as well as preparation methods and applications thereof | |
| AR018622A1 (en) | COMPOUNDS (S) - (-) - 1- [1- (4-SUBSTITUTED OR NOT REPLACED, 2-METOXIFENIL) PIPERID-4-IL] -N- (7-TRIFLUOROMETIL-2,3-DIHIDRO-1,4- BENZODIOXIN-2-IL METIL) METHYLAMINE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, ITS USE TO PREPARE A MEDICINAL PRODUCT AND PROCEDURE TO PREPARE THEM | |
| Augstein et al. | Adrenergic neurone blocking agents derived from 1, 4-benzodioxan | |
| WO2007144487A2 (en) | Dual molecules containing a peroxide derivative, their synthesis and therapeutic uses | |
| Modi et al. | Potential anticancer agents. III. Schiff bases from benzaldehyde nitrogen mustards and aminophenylthiazoles | |
| DE4341402A1 (en) | N-substituted azabicycloheptane derivatives, their preparation and use | |
| FR2899586A1 (en) | DIMERS OF ARTEMISININE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
| JPS5980668A (en) | Optically active derivative of n-arylated oxazolidin-2-one, manufacture and drug | |
| JPH07505120A (en) | Carbamate analogs of thiafizobenin, pharmaceutical compositions, and cholinesterase inhibition methods | |
| US4260762A (en) | Octahydro-1H-pyrrolo[2,3-g]isoquinolines | |
| CN110156822A (en) | A kind of naphthol-phenylboronic acid compound and its preparation method and application | |
| JPS60158190A (en) | Hydantoin derivative, its preparation, and drug containing it | |
| Jin et al. | Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT1F receptor agonists for migraine therapy | |
| US20040039023A1 (en) | Therapeutic agents | |
| CN1445217A (en) | Substitutional ramification of tetrahydro-isoquinoline, as well as its preparing method and its medication compound containing them | |
| CN106883225A (en) | A kind of coumarin derivative with 1,2,4 oxadiazoles structure fragments and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |